Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2009 2
2011 1
2012 1
2013 2
2015 1
2016 1
2019 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sager, j[au] (162 results)?
CD70 is a potential target biomarker in peripheral T-cell lymphomas.
Marques-Piubelli ML, Sagert J, Pham MT, Will M, Henderson D, Tipton K, Iyer S, Lu W, Khan KB, Hamana L, Chapman JR, Thakral B, Xu J, Miranda RN, Jennings K, Solis LM, Vega F. Marques-Piubelli ML, et al. Among authors: sagert j. Histopathology. 2022 Aug;81(2):272-275. doi: 10.1111/his.14670. Epub 2022 May 10. Histopathology. 2022. PMID: 35474464 No abstract available.
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S, Serwer L, DuPage A, Elkins K, Chauhan N, Ravn M, Buchanan F, Wang L, Krimm M, Wong K, Sagert J, Tipton K, Moore SJ, Huang Y, Jang A, Ureno E, Miller A, Patrick S, Duvur S, Liu S, Vasiljeva O, Li Y, Henriques T, Badagnani I, Jeffries S, Schleyer S, Leanna R, Krebber C, Viswanathan S, Desnoyers L, Terrett J, Belvin M, Morgan-Lappe S, Kavanaugh WM, Richardson J. Singh S, et al. Among authors: sagert j. Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336. doi: 10.1158/1535-7163.MCT-21-0193. Mol Cancer Ther. 2022. PMID: 35666803 Free PMC article.
Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody.
Stroh M, Sagert J, Burke JM, Apgar JF, Lin L, Millard BL, Michael Kavanaugh W. Stroh M, et al. Among authors: sagert j. CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):676-684. doi: 10.1002/psp4.12448. Epub 2019 Jul 26. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31250966 Free PMC article.
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Assi HH, Wong C, Tipton KA, Mei L, Wong K, Razo J, Chan C, Howng B, Sagert J, Krimm M, Diep L, Jang A, Nguyen MT, Lapuyade N, Singson V, Villanueva R, Paidhungat M, Liu S, Rangan V, Vasiljeva O, West JW, Richardson JH, Irving B, Daniel D, Belvin M, Kavanaugh WM. Assi HH, et al. Among authors: sagert j. Cancer Immunol Res. 2021 Dec;9(12):1451-1464. doi: 10.1158/2326-6066.CIR-21-0031. Epub 2021 Oct 11. Cancer Immunol Res. 2021. PMID: 34635485 Free PMC article.
PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.
Pandya K, Wyatt D, Gallagher B, Shah D, Baker A, Bloodworth J, Zlobin A, Pannuti A, Green A, Ellis IO, Filipovic A, Sagert J, Rana A, Albain KS, Miele L, Denning MF, Osipo C. Pandya K, et al. Among authors: sagert j. Clin Cancer Res. 2016 Jan 1;22(1):175-86. doi: 10.1158/1078-0432.CCR-15-0179. Epub 2015 Sep 8. Clin Cancer Res. 2016. PMID: 26350262 Free PMC article.
Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, Sagert JG, Hostetter DR, Han F, Gee J, Flandez J, Markham K, Nguyen M, Krimm M, Wong KR, Liu S, Daugherty PS, West JW, Lowman HB. Desnoyers LR, et al. Among authors: sagert jg. Sci Transl Med. 2013 Oct 16;5(207):207ra144. doi: 10.1126/scitranslmed.3006682. Sci Transl Med. 2013. PMID: 24132639
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.
Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, Carter BS, Maus MV. Choi BD, et al. Among authors: sagert jg. J Immunother Cancer. 2019 Nov 14;7(1):304. doi: 10.1186/s40425-019-0806-7. J Immunother Cancer. 2019. PMID: 31727131 Free PMC article.
14 results